RECRUITING

Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

Description

The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.

Study Overview

Study Details

Study overview

The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.

Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction (MM-HFpEF) A HeartShare Clinical Study

Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Chicago

Northwestern University, Chicago, Illinois, United States, 60611

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21287

Boston

Mass General Brigham, Boston, Massachusetts, United States, 02114

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Winston-Salem

Wake Forest University, Winston-Salem, North Carolina, United States, 27157

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * HFpEF criteria
  • 1. Age ≥30 years.
  • 2. Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability)
  • 3. Definition of HFpEF: signs and/or symptoms of HF, NYHA functional class II-IV, and at least one of the following:
  • 1. Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
  • 2. Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels \[using the thresholds listed above\], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).
  • 3. Previously documented elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise).
  • 4. Elevated H2FPEF score69 (≥5) or HFA-PEFF70 score (≥5).
  • 1. Age ≥30 years.
  • 2. Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability)
  • 3. Signs and/or symptoms of HF, NYHA functional class II-IV and all of the following:
  • 1. Does not meet BNP or NT-proBNP criteria for HFpEF (above)
  • 2. No prior HF hospitalization meeting HF criteria (above)
  • 3. No previous hemodynamic catheterization documentation of HF (as above)
  • * 1. Inadequate echo or fluoroscopic images.
  • 2. Neck anatomy unfavorable for jugular venous cannulation
  • 3. Therapy with direct oral anticoagulants without cessation for a period (age, renal function, and agent specific) deemed adequate to normalize coagulation according to local clinical guidelines.
  • 4. Previous or ongoing therapy with warfarin with INR ≥ 1.6 measured day before or of EMB
  • 5. Platelet count \< 50,000/ml
  • 6. Active bleeding or coagulation disorder
  • 7. Infection or fever
  • 8. Endocarditis
  • 9. Pregnancy
  • 10. Intracardiac thrombus
  • 11. RV Aneurysm
  • 12. Clinically significant tricuspid, pulmonary or aortic valve stenosis
  • 13. Tricuspid or pulmonary mechanical valve prosthesis
  • 14. Left bundle branch block

Ages Eligible for Study

30 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Northwestern University,

Sanjiv Shah, MD, PRINCIPAL_INVESTIGATOR, Northwestern University

Margaret Redfield, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2026-06